Bartlett A, Costa A, Martinez L, Roser R, Sagarra R, Sanchez J
Research Centre, Laboratorios Dr Esteve SA, Barcelona, Spain.
Eur J Drug Metab Pharmacokinet. 1992 Jul-Sep;17(3):195-9. doi: 10.1007/BF03190145.
Droxicam is a new anti-inflammatory drug which is a pro-drug of piroxicam and possesses delayed absorption kinetics. In this study, the comparative bioavailability of the two compounds was investigated. The study was performed following a cross-over design with single (20 mg) and multiple (20 mg/day for 30 consecutive days) administration in 25 healthy volunteers. The peak plasma concentrations of piroxicam, obtained following administration of droxicam, were lower than those calculated for administration of piroxicam, and the time taken to reach these peak concentrations was increased by approximately 5-7 h. There was no significant difference in either the elimination kinetics of piroxicam or the AUC values found following administration of the two products. Bioavailability of droxicam is equal to that of piroxicam, with a slower rate of absorption.
屈昔康是一种新型抗炎药物，它是吡罗昔康的前体药物，具有延迟吸收动力学。在本研究中，对这两种化合物的相对生物利用度进行了研究。该研究采用交叉设计，在25名健康志愿者中进行单次（20毫克）和多次（连续30天每天20毫克）给药。服用屈昔康后测得的吡罗昔康血浆峰浓度低于服用吡罗昔康时计算得出的浓度，达到这些峰浓度所需的时间增加了约5 - 7小时。两种产品给药后吡罗昔康的消除动力学或AUC值均无显著差异。屈昔康的生物利用度与吡罗昔康相等，但吸收速率较慢。
